Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

A Novel Method of Treating Apomorphine-Induced Subcutaneous Nodules.

Novo Ponte S, García Malo C, Blasco Quílez MR, Sánchez Alonso P.

Mov Disord Clin Pract. 2019 Nov 17;7(1):83-85. doi: 10.1002/mdc3.12853. eCollection 2020 Jan. No abstract available.

PMID:
31970216
2.

Quantitative transcranial sonography of the substantia nigra as a predictor of therapeutic response to intravenous iron therapy in restless legs syndrome.

Garcia-Malo C, Wanner V, Miranda C, Romero Peralta S, Agudelo L, Cano-Pumarega I, Granizo JJ, Garcia-Borreguero D.

Sleep Med. 2020 Feb;66:123-129. doi: 10.1016/j.sleep.2019.09.020. Epub 2019 Oct 30.

PMID:
31875533
3.

Treating restless legs syndrome in the context of sleep disordered breathing comorbidity.

Romero-Peralta S, Cano-Pumarega I, Garcia-Malo C, Agudelo Ramos L, García-Borreguero D.

Eur Respir Rev. 2019 Oct 1;28(153). pii: 190061. doi: 10.1183/16000617.0061-2019. Print 2019 Sep 30. Review.

4.

Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome.

Wanner V, Garcia Malo C, Romero S, Cano-Pumarega I, García-Borreguero D.

Adv Pharmacol. 2019;84:187-205. doi: 10.1016/bs.apha.2019.02.003. Epub 2019 Mar 14. Review.

PMID:
31229171
5.

Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment.

Garcia-Borreguero D, Cano-Pumarega I, Garcia Malo C, Cruz Velarde JA, Granizo JJ, Wanner V.

Sleep Med. 2019 Mar;55:74-80. doi: 10.1016/j.sleep.2018.11.025. Epub 2018 Dec 26.

6.

Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis.

Garcia-Borreguero D, Guitart X, Garcia Malo C, Cano-Pumarega I, Granizo JJ, Ferré S.

Sleep Med. 2018 May;45:94-97. doi: 10.1016/j.sleep.2018.02.002. Epub 2018 Feb 24.

PMID:
29680437

Supplemental Content

Loading ...
Support Center